Patents by Inventor Lara Kallander

Lara Kallander has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • HYDROXY FORMAMIDE DERIVATIVES AND THEIR USE
    Publication number: 20200095217
    Abstract: Disclosed are compounds having the formula: wherein R1, R2 and R3 are as defined herein, and methods of making and using the same, including use as inhibitors of BMP1, TLL1 and/or TLL2 and in treatment of diseases associated with BMP1, TLL1 and/or TLL2 activity.
    Type: Application
    Filed: October 17, 2019
    Publication date: March 26, 2020
    Inventors: Sarah E. DOWDELL, Hilary Schenck EIDAM, Mark ELBAN, Ryan Michael FOX, Marlys HAMMOND, Mark A. HILFIKER, Tram H. HOANG, Lara KALLANDER, Brian Griffin LAWHORN, Sharada MANNS, Joanne PHILP, David G. WASHBURN, Guosen YE
  • Hydroxy formamide derivatives and their use
    Patent number: 10450288
    Abstract: Disclosed are compounds having the formula: wherein R1, R2 and R3 are as defined herein, and methods of making and using the same, including use as inhibitors of BMP1, TLL1 and/or TLL2 and in treatment of diseases associated with BMP1, TLL1 and/or TLL2 activity.
    Type: Grant
    Filed: January 9, 2015
    Date of Patent: October 22, 2019
    Assignee: GlaxoSmithKline Intellectual Property (No. 2) Limited
    Inventors: Sarah E. Dowdell, Hilary Schenck Eidam, Mark Elban, Ryan Michael Fox, Marlys Hammond, Mark A. Hilfiker, Tram H. Hoang, Lara Kallander, Brian Griffin Lawhorn, Sharada Manns, Joanne Philp, David G. Washburn, Guosen Ye
  • HYDROXY FORMAMIDE DERIVATIVES AND THEIR USE
    Publication number: 20160340328
    Abstract: Disclosed are compounds having the formula: wherein R1, R2 and R3 are as defined herein, and methods of making and using the same, including use as inhibitors of BMP1, TLL1 and/or TLL2 and in treatment of diseases associated with BMP1, TLL1 and/or TLL2 activity.
    Type: Application
    Filed: January 9, 2015
    Publication date: November 24, 2016
    Inventors: Sarah E. DOWDELL, Hilary Schenck EIDAM, Mark ELBAN, Ryan Michael FOX, Marlys HAMMOND, Mark A. HILFIKER, Tram H. HOANG, Lara KALLANDER, Brian Griffin LAWHORN, Sharada MANNS, Joanne PHILP, David G. WASHBURN, Guosen YE
  • Acid and ester compounds and methods of using the same
    Publication number: 20060041164
    Abstract: Disclosed is a compound of having the formula: pharmaceutically acceptable salts or solvates thereof and pharmaceutical compositions containing the same, wherein the structural variables are as defined herein. The compounds, salts and solvates of this invention are useful as LXR agonists.
    Type: Application
    Filed: March 26, 2003
    Publication date: February 23, 2006
    Inventors: Scott Thompson, Lara Kallander, Chun Ma, Joseph Marino, Dennis Lee
  • Compounds and methods
    Publication number: 20050165045
    Abstract: Disclosed is a compound of having the formula: pharmaceutically acceptable salts or solvates thereof and pharmaceutical compositions containing the same, wherein the structural variables are as defined herein. The compounds, salts and solvates of this invention are useful as LXR agonists.
    Type: Application
    Filed: March 26, 2003
    Publication date: July 28, 2005
    Inventors: Scott Thompson, James Frazee, Lara Kallander, Chun Ma, Joseph Marino, Michael Neeb, Ajita Bhat
  • Compounds and methods
    Publication number: 20050143578
    Abstract: Disclosed are compounds of the formula: wherein the formula variables are as defined herein. The compounds of this invention are non-peptide, reversible inhibitors of type 2 methionine aminopeptidase. Also disclosed is the use of such compounds in treating conditions mediated by angiogenesis, such as cancer, haemangioma, proliferative retinopathy, rheumatoid arthritis, atherosclerotic neovascularization, psoriasis, ocular neovascularization and obesity.
    Type: Application
    Filed: February 22, 2005
    Publication date: June 30, 2005
    Inventors: Lara Kallander, M. Ryan, Scott Thompson
  • Amide compounds and methods of using the same
    Publication number: 20050107444
    Abstract: Disclosed is a compound having the formula pharmaceutically acceptable salts or solvates thereof and pharmaceutical compositions containing the same, wherein the structural variables are as defined herein. The compounds, salts and solvates of this invention are useful as LXR agonists.
    Type: Application
    Filed: March 26, 2003
    Publication date: May 19, 2005
    Inventors: Scott Thompsom, James Frazee, Lara Kallander, Chun Ma, Joseph Marino, Michael Neeb, Ning Wang
  • Triazole inhibitors of type 2 methionine aminopeptidase
    Publication number: 20050004116
    Abstract: Disclosed are compounds which are non-peptide, reversible inhibitors of type 2 methionine aminopeptidase, useful in treating conditions mediated by angiogenesis, such as cancer, haemangioma, proliferative retinopathy, rheumatoid arthritis, atherosclerotic neovascularization, psoriasis, ocular neovascularization and obesity.
    Type: Application
    Filed: July 21, 2004
    Publication date: January 6, 2005
    Inventors: Lara Kallander, Scott Thompson